Vanda Pharmaceuticals Files 8-K on Financials
Ticker: VNDA · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Feb 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Vanda Pharma dropped an 8-K on Feb 13th - check it for financial updates.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on February 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signals that Vanda Pharmaceuticals is providing updated financial information and operational disclosures to the SEC, which is important for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not inherently present new risks, but the content of the 8-K itself could contain material information.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- February 13, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 20250213 (date) — Conformed Period of Report
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not include the specific details of these results or statements.
What is the significance of an 8-K filing for Vanda Pharmaceuticals?
An 8-K filing is a report of unscheduled material events or corporate changes that could be of importance to shareholders or the SEC, such as significant financial events or operational developments.
When was this 8-K filing submitted to the SEC?
The filing was submitted on February 13, 2025.
What is Vanda Pharmaceuticals' principal executive office address?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
What is Vanda Pharmaceuticals' IRS Employer Identification Number?
Vanda Pharmaceuticals Inc.'s IRS Employer Identification Number is 03-0491827.
Filing Stats: 1,011 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-02-13 16:08:05
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20250213.htm (8-K) — 36KB
- vnda8-k2132025exhibit991.htm (EX-99.1) — 139KB
- vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
- 0001628280-25-005406.txt ( ) — 424KB
- vnda-20250213.xsd (EX-101.SCH) — 3KB
- vnda-20250213_def.xml (EX-101.DEF) — 16KB
- vnda-20250213_lab.xml (EX-101.LAB) — 28KB
- vnda-20250213_pre.xml (EX-101.PRE) — 16KB
- vnda-20250213_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 13, 2025, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2024 (the "Earnings Call"). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are "forward-looking statements" under the securities laws, including, but not limited to, statements regarding Vanda's commercial products, plans and opportunities, as well as statements about Vanda's products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the strength of its business in the U.S. and Vanda's ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated February 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 13, 2025 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary